Ovidrel or Ovitrelle Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing infertility prevalence, wider acceptance of fertility treatments, clinical success of recombinant hCG therapies, expansion of fertility clinics, improved diagnostic capabilities for ovulation disorders.

The growth in the forecast period can be attributed to growing demand for ART procedures, rising maternal age globally, increasing investments in fertility healthcare infrastructure, broader insurance coverage for fertility treatments, expansion of home-administered fertility therapies. Major trends in the forecast period include increasing use of assisted reproductive technologies, rising adoption of pre-filled fertility injections, growing demand for ovulation induction therapies, expansion of fertility treatment accessibility, enhanced focus on patient-friendly drug delivery.

The rising infertility rates are expected to drive the growth of the Ovidrel or Ovitrelle market going forward. Infertility rates refer to the proportion of individuals or couples unable to conceive after a year of regular, unprotected intercourse. Factors such as delayed childbearing, lifestyle influences like obesity and stress, and environmental factors contribute to rising infertility. Ovidrel or Ovitrelle supports infertility treatment by inducing ovulation with recombinant human chorionic gonadotropin (hCG), facilitating egg release and increasing the chances of conception. For instance, in August 2025, according to the Canadian Fertility and Andrology Society, a UK-based national professional organization advancing reproductive medicine and science, around 8% of couples with female partners aged 15 to 45 in Canada are affected by infertility. Therefore, rising infertility rates are driving the growth of the Ovidrel or Ovitrelle market.

The rise in healthcare expenditure is expected to significantly propel the growth of the Ovidrel or Ovitrelle market. Healthcare expenditure refers to the total spending on medical services, treatments, and healthcare products within a system. Factors driving healthcare spending include aging populations, higher prevalence of chronic and infectious diseases, advancements in medical technology, and growing demand for quality healthcare services. Increased healthcare expenditure expands access to fertility treatments and enables more women, including those with PCOS, to afford medications like Ovidrel or Ovitrelle, supporting ovulation stimulation and improved fertility outcomes. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with 0.9% growth in 2022. Therefore, rising healthcare expenditure is driving the growth of the Ovidrel or Ovitrelle market.

The increasing prevalence of polycystic ovary syndrome (PCOS) is expected to propel the growth of the Ovidrel or Ovitrelle market. PCOS is a hormonal disorder characterized by irregular menstrual cycles, ovarian cysts, and elevated androgen levels, often associated with infertility and metabolic issues. Rising obesity rates, lifestyle changes, and improved awareness and diagnosis contribute to the growing prevalence of PCOS. Ovidrel or Ovitrelle assists women with PCOS by stimulating ovulation, triggering the release of mature eggs, and enhancing conception chances during fertility treatments. For instance, in June 2023, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, PCOS affects approximately 8-13% of women of reproductive age, with up to 70% of cases remaining undiagnosed. Therefore, the increasing prevalence of PCOS is driving the growth of the Ovidrel or Ovitrelle market.

Major companies operating in the ovidrel or ovitrelle market are Merck KGaA, Eli Lilly and Company.

North America was the largest region in the ovidrel or ovitrelle market in 2025. The regions covered in the ovidrel or ovitrelle market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ovidrel or ovitrelle market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are affecting the ovidrel or ovitrelle market by increasing costs of imported recombinant hormone ingredients, sterile injection components, biologic formulation equipment, and cold-chain distribution services. North America and Europe are most impacted due to reliance on specialized biologics manufacturing and cross-border supply chains, while emerging markets face higher import costs. These tariffs are raising treatment costs and influencing clinic procurement decisions. However, they are also driving regional biologics production, localized syringe filling operations, and strategic partnerships to strengthen supply continuity.

The ovidrel or ovitrelle market research report is one of a series of new reports that provides ovidrel or ovitrelle market statistics, including ovidrel or ovitrelle industry global market size, regional shares, competitors with a ovidrel or ovitrelle market share, detailed ovidrel or ovitrelle market segments, market trends and opportunities, and any further data you may need to thrive in the ovidrel or ovitrelle industry. This ovidrel or ovitrelle market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ovidrel, also marketed as Ovitrelle, is a prescription medication containing choriogonadotropin alfa, a synthetic version of the hormone human chorionic gonadotropin (hCG). It is used in fertility treatments to trigger ovulation or support the luteal phase in women undergoing assisted reproductive technologies. Ovidrel aids in egg maturation following ovarian stimulation and can also induce ovulation in women with conditions such as polycystic ovary syndrome (PCOS).

The main formulations of Ovidrel or Ovitrelle are pre-filled syringes and vials. Pre-filled syringes provide a ready-to-use, single-dose option for home administration, ensuring precise dosing and reducing the risk of contamination during fertility treatments. It is used in various indications, including assisted reproductive technology (ART) and ovulation induction, and is distributed through hospitals and clinics, retail pharmacies, and online pharmacies.

The ovidrel or ovitrelle market consists of sales of cartridges, auto-injectors, and pen devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.